{"hands_on_practices": [{"introduction": "The first step in any successful therapy is administering the correct amount of medication. This exercise grounds theoretical pharmacokinetics in a practical clinical scenario by asking you to calculate the oral dose of ivermectin needed to achieve a specific therapeutic concentration in the body [@problem_id:4923328]. By working through this problem, you will apply core concepts like bioavailability ($F$) and volume of distribution ($V_d$) to understand how clinicians translate abstract parameters into a tangible, effective dose for a patient.", "problem": "A single oral dose of ivermectin is planned for an adult patient to treat a nematode infection. Assume a one-compartment model with first-order elimination and very rapid first-order absorption relative to elimination, so that the time to peak is negligible compared to elimination. The maximum plasma concentration (Cmax) is targeted to be $40$ ng/mL. The absolute oral bioavailability (F) is $0.60$, the apparent volume of distribution (Vd) is $200$ L, and the first-order elimination rate constant (ke) is $0.035$ h$^{-1}$. Starting from mass balance and the definition of volume of distribution under the rapid absorption limit, derive the expression relating dose to peak concentration and compute the oral dose required to achieve the target maximum plasma concentration. Express the final dose in mg and round your answer to three significant figures.", "solution": "The problem is first validated for scientific soundness, self-consistency, and clarity.\n\n**Step 1: Extract Givens**\n- Model type: One-compartment model.\n- Elimination kinetics: First-order.\n- Absorption kinetics: First-order, very rapid relative to elimination.\n- Assumption: Time to peak concentration is negligible.\n- Target maximum plasma concentration ($C_{max}$): $40$ ng/mL.\n- Absolute oral bioavailability ($F$): $0.60$.\n- Apparent volume of distribution ($V_d$): $200$ L.\n- First-order elimination rate constant ($k_e$): $0.035$ h$^{-1}$.\n- Required output: Oral dose in mg, rounded to three significant figures.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem describes a standard, simplified pharmacokinetic scenario. The one-compartment model with first-order absorption and elimination is a cornerstone of clinical pharmacology. The assumption of \"very rapid absorption\" ($k_a \\gg k_e$) simplifies the full model, allowing the peak concentration to be approximated as occurring at time zero, which is a common and valid simplification for drugs that are absorbed quickly. The given pharmacokinetic parameters ($F$, $V_d$, $k_e$) are within a plausible physiological range for a drug like ivermectin. The problem is scientifically grounded, well-posed with all necessary information provided to find a unique solution, and stated objectively. The elimination rate constant $k_e$ is provided but is not necessary for the calculation of the dose to achieve $C_{max}$ under the rapid absorption assumption; its presence serves to completely define the model but does not create a contradiction.\n\n**Step 3: Verdict and Action**\nThe problem is valid. A solution will be derived.\n\n**Derivation and Solution**\nThe problem requires the derivation of the relationship between the oral dose and the maximum plasma concentration under the specified conditions, followed by the calculation of the required dose.\n\nThe fundamental relationship in a one-compartment model between the amount of drug in the body, $A(t)$, and the plasma concentration, $C(t)$, is given by the definition of the apparent volume of distribution, $V_d$:\n$$ A(t) = V_d \\cdot C(t) $$\n\nFor an oral administration, the dose that reaches the systemic circulation (the bioavailable dose) is the product of the administered dose, $\\text{Dose}$, and the absolute oral bioavailability, $F$.\n$$ \\text{Bioavailable Dose} = F \\cdot \\text{Dose} $$\n\nThe problem states that absorption is very rapid relative to elimination. This is a critical simplifying assumption ($k_a \\gg k_e$), which implies that the entire bioavailable dose enters the systemic circulation almost instantaneously. In this limiting case, the absorption phase is negligible, and the peak plasma concentration, $C_{max}$, occurs at time $t \\approx 0$. The concentration profile mimics that of an intravenous bolus injection of an amount equal to the bioavailable dose.\n\nTherefore, at time $t=0$, the amount of drug in the body, $A(0)$, is equal to the full bioavailable dose:\n$$ A(0) = F \\cdot \\text{Dose} $$\n\nAlso at time $t=0$, the plasma concentration is at its maximum, $C(0) = C_{max}$. Using the definition of the volume of distribution at this time point:\n$$ A(0) = V_d \\cdot C(0) = V_d \\cdot C_{max} $$\n\nBy equating the two expressions for $A(0)$, we derive the desired relationship between the oral dose and the peak concentration:\n$$ F \\cdot \\text{Dose} = V_d \\cdot C_{max} $$\n\nTo compute the required oral dose, we rearrange this expression:\n$$ \\text{Dose} = \\frac{V_d \\cdot C_{max}}{F} $$\n\nThe given parameters are:\n- $V_d = 200$ L\n- $C_{max} = 40$ ng/mL\n- $F = 0.60$ (dimensionless)\n\nBefore substituting the values, we must ensure the units are consistent. The volume is in liters (L) and the concentration is in nanograms per milliliter (ng/mL). We will convert the concentration unit to ng/L to be consistent with the volume unit.\n$$ C_{max} = 40 \\frac{\\text{ng}}{\\text{mL}} \\times \\frac{1000 \\text{ mL}}{1 \\text{ L}} = 40000 \\frac{\\text{ng}}{\\text{L}} $$\n\nNow, we can substitute the numerical values into the equation for the dose:\n$$ \\text{Dose} = \\frac{(200 \\text{ L}) \\times (40000 \\frac{\\text{ng}}{\\text{L}})}{0.60} $$\n$$ \\text{Dose} = \\frac{8000000 \\text{ ng}}{0.60} $$\n$$ \\text{Dose} = 13333333.33... \\text{ ng} $$\n\nThe problem asks for the final dose to be expressed in milligrams (mg). We use the conversion factor $1 \\text{ mg} = 10^6 \\text{ ng}$:\n$$ \\text{Dose} = (13333333.33... \\text{ ng}) \\times \\frac{1 \\text{ mg}}{10^6 \\text{ ng}} = 13.333333... \\text{ mg} $$\n\nFinally, we round the answer to three significant figures as requested:\n$$ \\text{Dose} \\approx 13.3 \\text{ mg} $$", "answer": "$$ \\boxed{13.3} $$", "id": "4923328"}, {"introduction": "A drug's effectiveness depends on its ability to engage its molecular target. This practice delves into this crucial interaction by examining how mebendazole binds to its target, $\\beta$-tubulin, within the intestinal lumen where helminths reside [@problem_id:4923368]. You will derive the fundamental equation for fractional target occupancy and use it to understand a key principle of many antihelminthics: achieving a high local drug concentration at the site of infection is more important than high systemic levels, which minimizes the risk of side effects.", "problem": "A benzimidazole antihelminthic, mebendazole, exerts its pharmacodynamic effect by binding to helminth $\\beta$-tubulin within the intestinal lumen, impairing microtubule formation. Consider a single oral dose administered to an adult, after which solubility-limited dissolution leads to a total dissolved mebendazole concentration in the small intestinal lumen of $40\\,\\mu\\mathrm{M}$ sustained over several hours. Due to binding to dietary components and mucus, the fraction unbound in the lumen is $0.25$. An in vitro measurement against helminth $\\beta$-tubulin yields a dissociation constant $K_{d}=0.20\\,\\mu\\mathrm{M}$ under physiological ionic strength.\n\nAssume a single-site reversible binding equilibrium at the luminal surface, rapid equilibration relative to the dosing interval, and that the pharmacologically relevant free drug concentration approximates the dissolved unbound luminal concentration. Starting from the equilibrium definition of the dissociation constant $K_{d}$ and the definition of fractional occupancy, derive the expression for target site occupancy as a function of free drug concentration and $K_{d}$. Then, using the given parameters, calculate the fractional occupancy at the intestinal luminal site of action for mebendazole.\n\nFinally, briefly explain, based on the relationship between local luminal concentration and target occupancy, why systemic exposure is often unnecessary for soil-transmitted helminths (STH) such as Ascaris, Trichuris, and hookworms, while remaining consistent with pharmacokinetic-pharmacodynamic principles.\n\nExpress the occupancy as a unitless decimal fraction and round your numerical result to four significant figures.", "solution": "The problem is evaluated as scientifically grounded, well-posed, and objective. All necessary parameters and assumptions are provided to derive an expression for target site occupancy and to calculate its numerical value. The underlying principles are standard concepts in receptor theory and pharmacokinetic-pharmacodynamic (PK/PD) modeling. Thus, the problem is deemed valid.\n\nThe problem requires a three-part response: first, the derivation of the fractional occupancy equation; second, the calculation of the fractional occupancy for mebendazole at its luminal target; and third, a brief explanation of the relevance of local versus systemic drug concentrations.\n\n**Part 1: Derivation of an expression for fractional occupancy**\n\nLet $[D]$ represent the concentration of the free drug, $[R]$ represent the concentration of the free receptor (target site, in this case helminth $\\beta$-tubulin), and $[DR]$ represent the concentration of the drug-receptor complex. The total concentration of receptors, $[R_T]$, is the sum of free and bound receptors:\n$$[R_T] = [R] + [DR]$$\n\nThe interaction is described as a single-site reversible binding equilibrium:\n$$D + R \\rightleftharpoons DR$$\n\nThe dissociation constant, $K_d$, is defined by the law of mass action at equilibrium as the ratio of the product of the concentrations of the dissociated species to the concentration of the complex:\n$$K_d = \\frac{[D][R]}{[DR]}$$\n\nFractional occupancy, denoted by $\\theta$, is defined as the fraction of the total receptor population that is occupied by the drug at equilibrium:\n$$\\theta = \\frac{[DR]}{[R_T]}$$\n\nOur goal is to express $\\theta$ as a function of $[D]$ and $K_d$. To do this, we must eliminate $[R]$ and $[DR]$ from the expression for $\\theta$.\n\nFrom the definition of $K_d$, we can express the free receptor concentration $[R]$ in terms of $[D]$, $[DR]$, and $K_d$:\n$$[R] = \\frac{K_d [DR]}{[D]}$$\n\nNow, substitute this expression for $[R]$ into the equation for the total receptor concentration $[R_T]$:\n$$[R_T] = \\frac{K_d [DR]}{[D]} + [DR]$$\n\nFactor out the common term $[DR]$ from the right-hand side:\n$$[R_T] = [DR] \\left( \\frac{K_d}{[D]} + 1 \\right)$$\n\nBy finding a common denominator, this can be written as:\n$$[R_T] = [DR] \\left( \\frac{K_d + [D]}{[D]} \\right)$$\n\nNow, we substitute this expression for $[R_T]$ into the definition of fractional occupancy, $\\theta$:\n$$\\theta = \\frac{[DR]}{[DR] \\left( \\frac{K_d + [D]}{[D]} \\right)}$$\n\nThe term $[DR]$ cancels from the numerator and the denominator, yielding:\n$$\\theta = \\frac{1}{\\frac{K_d + [D]}{[D]}}$$\n\nSimplifying the complex fraction gives the final derived expression for fractional occupancy, commonly known as the Hill-Langmuir equation for single-site binding:\n$$\\theta = \\frac{[D]}{[D] + K_d}$$\n\n**Part 2: Calculation of fractional occupancy**\n\nThe problem provides the necessary parameters to calculate $\\theta$. The pharmacologically relevant free drug concentration, $[D]$, is stated to be the dissolved unbound luminal concentration. This is calculated from the total dissolved luminal concentration, $C_{\\text{total, lumen}}$, and the fraction unbound, $f_u$.\n\nGiven:\nTotal dissolved luminal concentration, $C_{\\text{total, lumen}} = 40\\,\\mu\\mathrm{M}$\nFraction unbound in the lumen, $f_u = 0.25$\n\nThe free drug concentration $[D]$ is therefore:\n$$[D] = f_u \\times C_{\\text{total, lumen}} = 0.25 \\times 40\\,\\mu\\mathrm{M} = 10\\,\\mu\\mathrm{M}$$\n\nThe dissociation constant for the binding of mebendazole to helminth $\\beta$-tubulin is given as:\n$$K_d = 0.20\\,\\mu\\mathrm{M}$$\n\nUsing the derived expression for fractional occupancy, we can now substitute these values:\n$$\\theta = \\frac{[D]}{[D] + K_d} = \\frac{10\\,\\mu\\mathrm{M}}{10\\,\\mu\\mathrm{M} + 0.20\\,\\mu\\mathrm{M}}$$\n\nThe units ($\\mu\\mathrm{M}$) cancel out, as expected for a unitless fraction:\n$$\\theta = \\frac{10}{10.20}$$\n\nCalculating the numerical value:\n$$\\theta \\approx 0.980392156...$$\n\nRounding the result to four significant figures, as requested:\n$$\\theta \\approx 0.9804$$\n\n**Part 3: Explanation**\n\nThe calculated fractional occupancy at the intestinal luminal site of action is approximately $0.9804$, or $98.04\\%$. This is a very high degree of target engagement. The pharmacodynamic effect of an antihelminthic like mebendazole is exerted by binding to its target, $\\beta$-tubulin, within the worm. For soil-transmitted helminths (STH) such as *Ascaris*, *Trichuris*, and hookworms, the adult parasites reside within the gastrointestinal lumen.\n\nThe calculation demonstrates that the local, free concentration of mebendazole in the intestinal lumen ($[D] = 10\\,\\mu\\mathrm{M}$) is substantially higher than its dissociation constant ($K_d = 0.20\\,\\mu\\mathrm{M}$). Specifically, the free drug concentration is $50$ times the $K_d$ value. According to the occupancy equation, when $[D] \\gg K_d$, the occupancy $\\theta$ approaches its maximum value of $1$. This high local concentration ensures near-maximal saturation of the target sites on the helminth, leading to potent inhibition of microtubule function and subsequent paralysis and death of the parasite.\n\nBecause the site of infection and the site of action are both within the GI tract, a sufficient therapeutic effect can be achieved without the drug needing to be absorbed into the systemic circulation. Systemic exposure is only required for drugs whose pharmacological target is located in tissues and organs outside the GI tract. For drugs targeting intraluminal parasites, poor systemic absorption is often a desirable property, as it maximizes the drug concentration at the site of action and minimizes the potential for systemic side effects. This principle exemplifies targeted drug action, where a high local concentration drives a potent local effect, rendering systemic exposure unnecessary for efficacy.", "answer": "$$\n\\boxed{0.9804}\n$$", "id": "4923368"}, {"introduction": "Why is a potent anti-parasitic drug like ivermectin safe for most mammals but neurotoxic for others? This exercise explores the critical role of physiological barriers, specifically the P-glycoprotein (P-gp) efflux pump at the blood-brain barrier, in maintaining drug safety [@problem_id:4923342]. By modeling how P-gp limits ivermectin's entry into the central nervous system, you will quantify the dramatic increase in brain exposure when this protective mechanism fails, providing a clear example of 'pharmacokinetic selectivity'.", "problem": "Ivermectin is an antihelminthic drug that selectively targets nematode glutamate-gated chloride channels, but in mammals it can potentiate gamma-aminobutyric acid type A receptors at sufficiently high concentrations in the central nervous system. P-glycoprotein (P-gp), also known as ATP-binding cassette subfamily B member 1 (ABCB1), is an adenosine triphosphate-dependent efflux transporter highly expressed at the blood–brain barrier (BBB). Its activity limits central nervous system exposure to many xenobiotics, including ivermectin. In hosts with deficient or inhibited P-glycoprotein (for example, ABCB1 loss-of-function variants), ivermectin brain exposure rises and neurotoxicity can occur despite its parasitic receptor selectivity.\n\nConsider a pharmacokinetic model in which unbound ivermectin in the brain is described by a single, well-stirred brain compartment with first-order influx and efflux across the BBB. Let the unbound influx clearance from plasma to brain be $CL_{\\mathrm{in}}$ and the unbound efflux clearance from brain to plasma be the sum of a passive component $CL_{\\mathrm{pass}}$ and an active P-glycoprotein component $CL_{\\mathrm{pgp}}$. Assume a constant unbound plasma concentration is maintained such that a steady state can be considered for the brain. In a P-glycoprotein–deficient state, the active component is reduced by a multiplicative factor $r$ (where $0 \\leq r \\leq 1$), so that the effective active efflux becomes $r\\,CL_{\\mathrm{pgp}}$.\n\nUsing receptor selectivity and the role of P-glycoprotein at the BBB, first explain mechanistically why ivermectin can cause neurotoxicity in P-glycoprotein–deficient hosts even though its primary parasitic target is absent in mammals. Then, starting from mass balance at steady state for the unbound brain compartment, derive the analytic expression for the fold-change in steady-state unbound brain concentration when P-glycoprotein activity is reduced by the factor $r$, and evaluate this fold-change numerically for $CL_{\\mathrm{pass}} = 0.05$ mL$\\cdot$min$^{-1}\\cdot$g$^{-1}$, $CL_{\\mathrm{pgp}} = 0.25$ mL$\\cdot$min$^{-1}\\cdot$g$^{-1}$, and $r = 0.1$. Round your final fold-change to four significant figures. Express the final result as a dimensionless fold-change number (no units).", "solution": "The problem statement is evaluated to be scientifically grounded, well-posed, and objective. It presents a standard pharmacokinetic compartmental analysis problem based on established principles of drug transport and toxicology. All necessary definitions and parameters are provided for a unique solution. The problem is valid.\n\nThe solution proceeds in two parts as requested: first, a mechanistic explanation of ivermectin neurotoxicity in the context of P-glycoprotein deficiency, and second, a quantitative derivation and calculation of the change in brain exposure.\n\n**Part 1: Mechanistic Explanation of Neurotoxicity**\n\nIvermectin's high therapeutic index in most mammals stems from a combination of target selectivity and limited access to the central nervous system (CNS). Its primary antihelminthic effect is mediated by the potentiation of glutamate-gated chloride channels, which are specific to invertebrates and absent in mammals. However, at sufficiently high concentrations, ivermectin can allosterically potentiate the action of $\\gamma$-aminobutyric acid (GABA) at GABA type A (GABA$_{\\mathrm{A}}$) receptors in the mammalian CNS. GABA is the principal inhibitory neurotransmitter in the brain; its potentiation by ivermectin leads to excessive neuronal inhibition, manifesting as clinical neurotoxicity (e.g., ataxia, depression, coma).\n\nUnder normal physiological conditions, the blood–brain barrier (BBB) effectively shields the CNS from high concentrations of ivermectin. This protection is not merely a passive diffusion barrier but is actively maintained by efflux transporters. P-glycoprotein (P-gp), encoded by the ABCB1 gene, is a key ATP-dependent efflux pump highly expressed on the luminal membrane of brain capillary endothelial cells. It recognizes ivermectin as a substrate and actively transports it from the brain back into the bloodstream. This efflux counteracts the passive influx, keeping the steady-state concentration of ivermectin in the brain low and below the threshold required to significantly modulate GABA$_{\\mathrm{A}}$ receptors.\n\nIn hosts with deficient P-gp function (e.g., due to homozygous ABCB1 loss-of-function mutations, as seen in certain dog breeds, or due to co-administration of a P-gp inhibitor), this active efflux mechanism is compromised. The efflux clearance from the brain is significantly reduced. As the influx from plasma remains unchanged, the mass balance shifts, leading to the accumulation of ivermectin within the CNS. The concentration can then rise to levels sufficient to potentiate GABA$_{\\mathrm{A}}$ receptors, precipitating the signs of neurotoxicity. Therefore, the toxicity is not due to a lack of receptor selectivity per se, but rather a failure of the physiological barrier that normally ensures 'pharmacokinetic selectivity' by preventing the drug from reaching its mammalian off-target site at toxic concentrations.\n\n**Part 2: Derivation and Calculation of Fold-Change**\n\nLet $C_{\\mathrm{u,p}}$ be the constant unbound ivermectin concentration in plasma and $C_{\\mathrm{u,b}}$ be the unbound ivermectin concentration in the brain compartment. The problem describes the system using first-order clearances. The rate of mass transfer into the brain ($\\text{Rate}_{\\mathrm{in}}$) and out of the brain ($\\text{Rate}_{\\mathrm{out}}$) can be expressed as:\n$$ \\text{Rate}_{\\mathrm{in}} = CL_{\\mathrm{in}} \\cdot C_{\\mathrm{u,p}} $$\n$$ \\text{Rate}_{\\mathrm{out}} = CL_{\\mathrm{out}} \\cdot C_{\\mathrm{u,b}} $$\nwhere $CL_{\\mathrm{in}}$ is the unbound influx clearance and $CL_{\\mathrm{out}}$ is the total unbound efflux clearance.\n\nAt steady state, the rate of change of drug mass in the brain is zero, which implies that the rate of influx equals the rate of efflux:\n$$ \\text{Rate}_{\\mathrm{in}} = \\text{Rate}_{\\mathrm{out}} $$\n$$ CL_{\\mathrm{in}} \\cdot C_{\\mathrm{u,p}} = CL_{\\mathrm{out}} \\cdot C_{\\mathrm{u,b,ss}} $$\nSolving for the steady-state unbound brain concentration, $C_{\\mathrm{u,b,ss}}$:\n$$ C_{\\mathrm{u,b,ss}} = C_{\\mathrm{u,p}} \\cdot \\frac{CL_{\\mathrm{in}}}{CL_{\\mathrm{out}}} $$\n\nWe can now apply this general formula to the two specified conditions: the normal (wild-type) state and the P-gp-deficient state.\n\n**Normal (Wild-Type) State:**\nIn a host with fully functional P-glycoprotein, the total efflux clearance, $CL_{\\mathrm{out,WT}}$, is the sum of the passive and active components:\n$$ CL_{\\mathrm{out,WT}} = CL_{\\mathrm{pass}} + CL_{\\mathrm{pgp}} $$\nThe steady-state unbound brain concentration in this state, $C_{\\mathrm{u,b,WT}}$, is:\n$$ C_{\\mathrm{u,b,WT}} = C_{\\mathrm{u,p}} \\cdot \\frac{CL_{\\mathrm{in}}}{CL_{\\mathrm{pass}} + CL_{\\mathrm{pgp}}} $$\n\n**P-gp-Deficient State:**\nIn the deficient state, the P-gp active transport component, $CL_{\\mathrm{pgp}}$, is reduced by a multiplicative factor $r$. The total efflux clearance in this state, $CL_{\\mathrm{out,D}}$, becomes:\n$$ CL_{\\mathrm{out,D}} = CL_{\\mathrm{pass}} + r \\cdot CL_{\\mathrm{pgp}} $$\nThe corresponding steady-state unbound brain concentration, $C_{\\mathrm{u,b,D}}$, is:\n$$ C_{\\mathrm{u,b,D}} = C_{\\mathrm{u,p}} \\cdot \\frac{CL_{\\mathrm{in}}}{CL_{\\mathrm{pass}} + r \\cdot CL_{\\mathrm{pgp}}} $$\n\n**Fold-Change Derivation:**\nThe fold-change is defined as the ratio of the steady-state concentration in the deficient state to that in the normal state:\n$$ \\text{Fold-Change} = \\frac{C_{\\mathrm{u,b,D}}}{C_{\\mathrm{u,b,WT}}} $$\nSubstituting the expressions derived above:\n$$ \\text{Fold-Change} = \\frac{C_{\\mathrm{u,p}} \\cdot \\frac{CL_{\\mathrm{in}}}{CL_{\\mathrm{pass}} + r \\cdot CL_{\\mathrm{pgp}}}}{C_{\\mathrm{u,p}} \\cdot \\frac{CL_{\\mathrm{in}}}{CL_{\\mathrm{pass}} + CL_{\\mathrm{pgp}}}} $$\nThe terms $C_{\\mathrm{u,p}}$ and $CL_{\\mathrm{in}}$ cancel, yielding the final analytical expression for the fold-change:\n$$ \\text{Fold-Change} = \\frac{CL_{\\mathrm{pass}} + CL_{\\mathrm{pgp}}}{CL_{\\mathrm{pass}} + r \\cdot CL_{\\mathrm{pgp}}} $$\n\n**Numerical Evaluation:**\nWe are given the following values:\n$CL_{\\mathrm{pass}} = 0.05$ mL$\\cdot$min$^{-1}\\cdot$g$^{-1}$\n$CL_{\\mathrm{pgp}} = 0.25$ mL$\\cdot$min$^{-1}\\cdot$g$^{-1}$\n$r = 0.1$\n\nSubstituting these values into the derived expression:\n$$ \\text{Fold-Change} = \\frac{0.05 + 0.25}{0.05 + (0.1) \\cdot (0.25)} $$\n$$ \\text{Fold-Change} = \\frac{0.30}{0.05 + 0.025} $$\n$$ \\text{Fold-Change} = \\frac{0.30}{0.075} $$\n$$ \\text{Fold-Change} = 4 $$\nThe result is an exact integer. To express this with the requested four significant figures, we write it as $4.000$. This indicates that a $90\\%$ reduction in P-gp activity leads to a $4$-fold increase in the steady-state unbound ivermectin concentration in the brain.", "answer": "$$\n\\boxed{4.000}\n$$", "id": "4923342"}]}